Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8

BACKGROUND: Preclinical data suggest synergistic activity with the combination of programmed death-1 and cyclin-dependent kinase 4/6 blockade in oestrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2–) breast cancer. The noncomparative phase 1b/2 CheckMate 7A8 study (NCT04075...

Descripción completa

Detalles Bibliográficos
Autores principales: Jerusalem, Guy, Prat, Aleix, Salgado, Roberto, Reinisch, Mattea, Saura, Cristina, Borrego, Manuel Ruiz, Nikolinakos, Petros, Ades, Felipe, Filian, Jeiry, Huang, Ning, Mazzei-Abba, Antonella, Tolaney, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519837/
https://www.ncbi.nlm.nih.gov/pubmed/37741273
http://dx.doi.org/10.1016/j.breast.2023.103580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519837/
https://www.ncbi.nlm.nih.gov/pubmed/37741273
http://dx.doi.org/10.1016/j.breast.2023.103580

Ejemplares similares